18 Live Notices for عوامل الوكلاء المثبطة للمناعة
Showing 1 to 18
Ozanimod-Containing Medicinal Products
21 Jan 2025
24 Feb 2025Medicinal Products Containing Mycophenolate Mofetil
Lp Containing Mycophenolic Acid 2024
Selective Immunosuppressants - Ustekinumab Iv.
Selective Immunosuppressants - Ustekinumab Iv.
Selective Immunosuppressants - Ustekinumab Iv.
Delivery Of Medicinal Products And Medical Devices To The Military Institute Of Medicine – National Research Institute
Medicinal Products Containing Cyclosporine
PROVISION OF ANTITHYMOCYTE IMMUNOGLOBULIN (ATG) INJ&APIXABAN TABLET 5MG&FOSFOMYCIN ORAL GRANULES 3 GRAM&FLUDARABINE PHOSPHATE INJ 50 MG/VIAL&PEGFILGRASTIM 10 MG/ ML 0.6 ML PREFILLED SYRINGE [NEULASTIM]
PROVISION OF TOCILIZUMAB INJECTION 200 MG / 10 ML VIAL&RISANKIZUMAB 75MG INJ&IBUPROFEN TABLET 200 MG
Environmentally Friendly Supply Of Biological Human Medicines With Biosimilars For Public Health Centres In Valencia
Environmentally Friendly Supply Of Biological Human Medicines With Biosimilars For Public Health Centres In Valencia
Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Drugs With The Active Ingredient Abatacept (Atc Code: L04Aa24).
Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Drugs With The Active Ingredient Certolizumab Pegol (Atc Code: L04Ab05).
Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Drugs With The Active Ingredient Tocilizumab (Atc Code: L04Ac07).
Conclusion Of A Non-Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For Medicinal Products With The Active Ingredient Fingolimod (Atc Code: L04Aa27).
Conclusion Of A Non-Exclusive Discount Agreement In Accordance With § 130A Paragraph 8 Sgb V For Drugs With The Active Ingredient Infliximab (Atc Code: L04Ab02).
The Medicine Ravulizumab
Tenders by Country